skip to the content

The Avastin MoA suggests treatment until PD

PFS in NO16966

The phase III mCRC study NO16966 demonstrated the importance of treatment with Avastin until progression2,3

  • VEGF is expressed throughout the tumour life cycle1
    • continuous VEGF inhibition until PD with Avastin is therefore a rational approach to inhibit tumour growth and metastasis.
  
  • The efficacy benefits demonstrated with Avastin in clinical trials have occurred in the context of treatment until PD
    • in mCRC study NO16966, only 29% of patients in the Avastin arm received treatment until progression; median PFS was longer in this subgroup than in the general study population.2,3
    • Controlled clinical trials are currently underway to test the hypothesis that further benefit from Avastin may be obtained through treatment beyond PD.